OTCMKTS:IPHYF Innate Pharma (IPHYF) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free IPHYF Stock Alerts $2.49 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$2.49▼$2.4950-Day Range$2.13▼$2.7752-Week Range$2.13▼$3.36VolumeN/AAverage Volume1,625 shsMarket Capitalization$199.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Innate Pharma alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Innate Pharma Stock (OTCMKTS:IPHYF)Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Read More IPHYF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPHYF Stock News HeadlinesMay 28, 2024 | finance.yahoo.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesMay 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)April 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth PotentialMarch 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)February 26, 2024 | benzinga.comInnate Pharma Stock (OTC:IPHYF), Insider Trading ActivityFebruary 4, 2024 | markets.businessinsider.comInnate Pharma SA (IPHYF) Receives a Hold from Kepler CapitalJanuary 11, 2024 | seekingalpha.comInnate Pharma: Worth A Deeper LookJanuary 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)January 4, 2024 | marketwatch.comInnate Pharma Up 4% After FDA Lifts Partial Clinical Hold on LacutamabDecember 19, 2023 | msn.comInnate Pharma and Sanofi to license natural killer cell engagerDecember 14, 2023 | markets.businessinsider.comBuy Rating for Innate Pharma Backed by Promising Lacutamab Clinical Results and Regulatory ProspectsNovember 27, 2023 | finance.yahoo.comInnate Pharma to Host Virtual KOL Event on LacutamabNovember 7, 2023 | finance.yahoo.comInnate Pharma Announces Conference Call for Third Quarter 2023 Business UpdateOctober 27, 2023 | finance.yahoo.comInnate Pharma Announces Its Participation to Upcoming Investor ConferencesOctober 16, 2023 | finance.yahoo.comInnate Pharma Announces Abstracts Selected for ESMO Congress 2023October 5, 2023 | marketwatch.comInnate Pharma Shares Fall Premarket on FDA Partial Study HoldOctober 5, 2023 | msn.comRegulatory Hurdle For Innate Pharma's Blood Cancer StudiesOctober 5, 2023 | markets.businessinsider.comInnate Pharma Says FDA Places Partial Clinical Hold On Lacutamab IND; Stock Down 10%September 22, 2023 | finance.yahoo.comInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023July 11, 2023 | finance.yahoo.comFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJuly 7, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023June 18, 2023 | markets.businessinsider.comKepler Capital Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)June 8, 2023 | marketwatch.comADRs End Higher, Innate Pharma and Medigus Trade ActivelyJune 8, 2023 | marketwatch.comInnate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track DesignationMay 26, 2023 | finance.yahoo.comInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AMLSee More Headlines Receive IPHYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CUSIPN/A CIK1598599 Webwww.innate-pharma.com Phone(343) 030-3030Fax33-04-30-30-30-00Employees179Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual Sales$66.71 million Price / Sales2.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book3.56Miscellaneous Outstanding Shares80,210,000Free Float54,632,000Market Cap$199.72 million OptionableNot Optionable Beta1.13 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Herve Brailly Ph.D. (Age 63)Co-Founder, Interim CEO & Chairman of Executive Board Mr. Yannis Morel Ph.D. (Age 51)Executive VP, COO & Member of Executive Board Comp: $390.87kDr. François Romagné Ph.D. (Age 60)Founder Mr. Eric Vivier D.V.M. (Age 60)M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer Dr. Marc Bonneville Ph.D. (Age 64)Founder Mr. Jean Jacques Fournié Ph.D.FounderMr. Alessandro Moretta M.D.Ph.D., FounderMr. Frederic Lombard M.B.A. (Age 49)Senior VP & CFO Dr. Sonia Quaratino M.D. (Age 57)Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board Mr. Arvind SoodExecutive VP, President of US Operations & Member of Executive BoardMore ExecutivesKey CompetitorsMesoblastNASDAQ:MESOScholar RockNASDAQ:SRRKTaysha Gene TherapiesNASDAQ:TSHAProKidneyNASDAQ:PROKHilleVaxNASDAQ:HLVXView All Competitors IPHYF Stock Analysis - Frequently Asked Questions How have IPHYF shares performed in 2024? Innate Pharma's stock was trading at $2.84 on January 1st, 2024. Since then, IPHYF shares have decreased by 12.3% and is now trading at $2.49. View the best growth stocks for 2024 here. Are investors shorting Innate Pharma? Innate Pharma saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 5,500 shares, a decline of 6.8% from the April 30th total of 5,900 shares. Based on an average trading volume of 2,200 shares, the days-to-cover ratio is currently 2.5 days. View Innate Pharma's Short Interest. How do I buy shares of Innate Pharma? Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IPHYF) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.